archman-shuttestock-com

ArchMan / Shuttestock.com

27 April 2016Americas

ANDA litigation ‘up 68%’ since 2014, says report

Patent litigation related to Abbreviated New Drug Applications (ANDAs) has increased by nearly 70% in the last two years, a report has claimed.

Already registered?

Login to your account

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More features

AbbVie blocks Humira antitrust suit

WATCH: Enabling success—mastering s112 in the new era of life sciences patents

AstraZeneca suffers defeat over $7bn diabetes patent

US firm Brownstein nabs five from Crowell ‘at pivotal moment’

American Regent secures rare PI win in Hatch-Waxman dispute

WATCH: Patents s101—how to overcome the current complexity of patent eligibility in the US

In-house with Bayer: ‘Focus on quality early and stay close to inventors’

J&J sues over schizophrenia drug generic following patent victory